Advances in immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20230410-00106

Abstract

Abstract:

With the increasing understanding of the complex interaction between the tumor microenvironment and immune therapy， the role of immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma （HNSCC） has gained significant attention. Immune checkpoint inhibitors targeting programmed death-1 （PD-1） and programmed death-ligand 1 （PD-L1）， cytotoxic T-lymphocyte-associated protein-4 （CTLA-4）， and T cell immunoglobulin domain and mucin domain-3 （TIM-3）， such as pembrolizumab， durvalumab， tremelimumab， ipilimumab， and LY3321367， have been applied in numerous clinical trials as monotherapies and combination therapies for the treatment of recurrent or metastatic HNSCC. Further research into the efficacy and safety of these immune checkpoint inhibitors in clinical trials may provide more effective strategies for the treatment of patients with recurrent or metastatic HNSCC.

Key words: Head and neck neoplasms, Carcinoma， squamous cell, Therapy, Immune checkpoint inhibitors

Chen Xinyi, Weng Yiming, Wei Jiayan, Wang Jinsong, Peng Min. Advances in immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 553-557.

References 37

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Ruffin AT, Li H, Vujanovic L, et al. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment[J]. Nat Rev Cancer, 2023, 23(3): 173-188. DOI: 10.1038/s41568-022-00531-9.
[3]	Wang G, Zhang M, Cheng M, et al. Tumor microenvironment in head and neck squamous cell carcinoma: functions and regulatory mechanisms[J]. Cancer Lett, 2021, 507: 55-69. DOI: 10.1016/j.canlet.2021.03.009. pmid: 33741424
[4]	Yi M, Niu M, Xu L, et al. Regulation of PD-L1 expression in the tumor microenvironment[J]. J Hematol Oncol, 2021, 14(1): 10. DOI: 10.1186/s13045-020-01027-5.
[5]	Dai X, Gao Y, Wei W. Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy[J]. Semin Cancer Biol, 2022, 85: 246-252. DOI: 10.1016/j.semcancer.2021.04.002.
[6]	Carlisle JW, Steuer CE, Owonikoko TK, et al. An update on the immune landscape in lung and head and neck cancers[J]. CA Cancer J Clin, 2020, 70(6): 505-517. DOI: 10.3322/caac.21630.
[7]	Botticelli A, Cirillo A, Strigari L, et al. Anti-PD-1 and anti-PD-L1 in head and neck cancer: a network meta-analysis[J]. Front Immunol, 2021, 12: 705096. DOI: 10.3389/fimmu.2021.705096.
[8]	Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016, 375(19): 1856-1867. DOI: 10.1056/NEJMoa1602252.
[9]	Gillison ML, Blumenschein G, Fayette J, et al. Long-term outcomes with nivolumab as first-line treatment in recurrent or metastatic head and neck cancer: subgroup analysis of CheckMate 141[J]. Oncologist, 2022, 27(2): e194-e198. DOI: 10.1093/oncolo/oyab036. pmid: 35641218
[10]	Chung CH, Li J, Steuer CE, et al. Phase Ⅱ multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2022, 28(11): 2329-2338. DOI: 10.1158/1078-0432.CCR-21-3849.
[11]	Wang H, Wang B, Wei J, et al. Molecular mechanisms underlying increased radiosensitivity in human papillomavirus-associated oropharyngeal squamous cell carcinoma[J]. Int J Biol Sci, 2020, 16(6): 1035-1043. DOI: 10.7150/ijbs.40880. pmid: 32140071
[12]	Griso AB, Acero-Riaguas L, Castelo B, et al. Mechanisms of cisplatin resistance in HPV negative head and neck squamous cell carcinomas[J]. Cells, 2022, 11(3): 561. DOI: 10.3390/cells11030561.
[13]	de Castro G Jr, Kudaba I, Wu YL, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score≥1% in the KEYNOTE-042 study[J]. J Clin Oncol, 2023, 41(11): 1986-1991. DOI: 10.1200/JCO.21.02885.
[14]	Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer[J]. N Engl J Med, 2023, 388(23): 2159-2170. DOI: 10.1056/NEJMoa2302312.
[15]	Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7): 956-965. DOI: 10.1016/S1470-2045(16)30066-3.
[16]	Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. pmid: 31679945
[17]	Mitchell TC, Hamid O, Smith DC, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase Ⅰ results from a multicenter, open-label phase Ⅰ/Ⅱ trial (ECHO-202/KEYNOTE-037)[J]. J Clin Oncol, 2018, 36(32): 3223-3230. DOI: 10.1200/JCO.2018.78.9602. pmid: 30265610
[18]	Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase Ⅱ study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy[J]. Eur J Cancer, 2019, 107: 142-152. DOI: 10.1016/j.ejca.2018.11.015. pmid: 30576970
[19]	Siu LL, Even C, Mesía R, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial[J]. JAMA Oncol, 2019, 5(2): 195-203. DOI: 10.1001/jamaoncol.2018.4628. pmid: 30383184
[20]	Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase Ⅲ study[J]. Ann Oncol, 2020, 31(7): 942-950. DOI: 10.1016/j.annonc.2020.04.001. pmid: 32294530
[21]	Huang X, Liu Q, Zhong G, et al. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): an open label, single-arm, phase Ⅰb clinical trial[J]. J Exp Clin Cancer Res, 2022, 41(1): 300. DOI: 10.1186/s13046-022-02510-2.
[22]	Xu Y, Gao Z, Hu R, et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy[J]. J Immunother Cancer, 2021, 9(10): e002699. DOI: 10.1136/jitc-2021-002699.
[23]	Park JS, Gazzaniga FS, Wu M, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance[J]. Nature, 2023, 617(7960): 377-385. DOI: 10.1038/s41586-023-06026-3.
[24]	Watanabe T, Ishino T, Ueda Y, et al. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity[J]. Cancer Sci, 2023, 114(5): 1859-1870. DOI: 10.1111/cas.15756.
[25]	Zappasodi R, Serganova I, Cohen IJ, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours[J]. Nature, 2021, 591(7851): 652-658. DOI: 10.1038/s41586-021-03326-4.
[26]	Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651[J]. J Clin Oncol, 2023, 41(12): 2166-2180. DOI: 10.1200/JCO.22.00332.
[27]	Psyrri A, Fayette J, Harrington K, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase Ⅲ study[J]. Ann Oncol, 2023, 34(3): 262-274. DOI: 10.1016/j.annonc.2022.12.008.
[28]	Gardner A, de Mingo Pulido Á, Hänggi K, et al. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8⁺ T cell and XCR1⁺dendritic cell spatial co-localization[J]. J Immunother Cancer, 2022, 10(1): e003571. DOI: 10.1136/jitc-2021-003571.
[29]	Wuerdemann N, Pütz K, Eckel H, et al. LAG-3, TIM-3 and VISTA expression on tumor-infiltrating lymphocytes in oropharyngeal squamous cell carcinoma-potential biomarkers for targeted therapy concepts[J]. Int J Mol Sci, 2020, 22(1): 379. DOI: 10.3390/ijms22010379.
[30]	Harding JJ, Moreno V, Bang YJ, et al. Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ⅰa/b study of LY3321367 with or without an anti-PD-L1 antibody[J]. Clin Cancer Res, 2021, 27(8): 2168-2178. DOI: 10.1158/1078-0432.CCR-20-4405. pmid: 33514524
[31]	Curigliano G, Gelderblom H, Mach N, et al. Phase Ⅰ/Ⅰb clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors[J]. Clin Cancer Res, 2021, 27(13): 3620-3629. DOI: 10.1158/1078-0432.CCR-20-4746. pmid: 33883177
[32]	Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape[J]. J Immunother Cancer, 2020, 8(1): e000911. DOI: 10.1136/jitc-2020-000911.
[33]	Sun F, Guo ZS, Gregory AD, et al. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer[J]. J Immunother Cancer, 2020, 8(1): e000294. DOI: 10.1136/jitc-2019-000294.
[34]	Maruhashi T, Sugiura D, Okazaki IM, et al. Binding of LAG-3 to stable peptide-MHC class Ⅱ limits T cell function and suppresses autoimmunity and anti-cancer immunity[J]. Immunity, 2022, 55(5): 912-924.e8. DOI: 10.1016/j.immuni.2022.03.013. pmid: 35413245
[35]	Jiang H, Ni H, Zhang P, et al. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity[J]. Oncoimmunology, 2021, 10(1): 1943180. DOI: 10.1080/2162402X.2021.1943180.
[36]	Clay TD, Majem M, Felip E, et al. Results from a phase Ⅱ study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma[J]. J Clin Oncol, 2021, 39(15_suppl): 9046. DOI: 10.1200/JCO.2021.39.15_suppl.9046.
[37]	Schöffski P, Tan DSW, Martín M, et al. Phase Ⅰ/Ⅱ study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies[J]. J Immunother Cancer, 2022, 10(2): e003776. DOI: 10.1136/jitc-2021-003776.